Paradigm Biocapital Advisors LP - 31 Dec 2025 SCHEDULE 13G/A Report for Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share (LXEO)

Filing Manager: Paradigm Biocapital Advisors LP
Reporting Manager: Paradigm BioCapital Advisors LP
Security: Lexeo Therapeutics, Inc. Common Stock, $0.0001 par value per share
Symbol: LXEO
Shares outstanding: 73,279,969 shares
Disclosed Ownership: 4,763,198 shares
Ownership: 6.5%
Form type: SCHEDULE 13G/A
Filing time: 17 Feb 2026, 16:02:14 UTC
Date of event: 31 Dec 2025
Previous filing: 20 Nov 2025
SEC: View on sec.gov

Reporting Managers (4)

Name	Ownership	Shares Owned	sole voting power	Signature	Title
Paradigm BioCapital Advisors LP	6.5%	4,763,198	4,763,198	/s/ David K. Kim	David K. Kim / Authorized Signatory
Paradigm BioCapital Advisors GP LLC	6.5%	4,763,198	4,763,198	/s/ David K. Kim	David K. Kim / Authorized Signatory
Senai Asefaw, M.D.	6.5%	4,763,198	4,763,198	/s/ Senai Asefaw, M.D.	N/A
Paradigm BioCapital International Fund Ltd.	5.8%	4,207,159	4,207,159	/s/ David K. Kim	David K. Kim / Authorized Signatory